Computational Simulation of Tumor-Induced Angiogenesis.
Angiogenesis
Cancer
Simulation
Systems biology
Tumor
Journal
Methods in molecular biology (Clifton, N.J.)
ISSN: 1940-6029
Titre abrégé: Methods Mol Biol
Pays: United States
ID NLM: 9214969
Informations de publication
Date de publication:
2023
2023
Historique:
entrez:
13
10
2022
pubmed:
14
10
2022
medline:
18
10
2022
Statut:
ppublish
Résumé
Cancer cells require higher oxygen levels and nutrition than normal cells. Cancer cells induce angiogenesis (the development of new blood vessels) from preexisting vessels. This biological process depends on the special, chemical, and physical properties of the microenvironment surrounding tumor tissues. The complexity of these properties hinders an understanding of their mechanisms. Various mathematical models have been developed to describe quantitative relationships related to angiogenesis. We developed a three-dimensional mathematical model that incorporates angiogenesis and tumor growth. We examined angiopoietin, which regulates the spouting and branching events in angiogenesis. The simulation successfully reproduced the transient decrease in new vessels during vascular network formation. This chapter describes the protocol used to perform the simulations.
Identifiants
pubmed: 36227549
doi: 10.1007/978-1-0716-2617-7_14
doi:
Substances chimiques
Angiopoietins
0
Oxygen
S88TT14065
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
275-283Informations de copyright
© 2023. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Wilson WR, Hay MP (2011) Targeting hypoxia in cancer therapy. Nat Rev Cancer 11(6):393–410
doi: 10.1038/nrc3064
Shweiki D, Itin A, Soffer D et al (1992) Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359(6398):843–845
doi: 10.1038/359843a0
Plate KH, Breier G, Weich HA et al (1992) Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359(6398):845–848
doi: 10.1038/359845a0
Folkman J, Klagsbrun M (1987) Angiogenic factors. Science 235(4787):442–447
doi: 10.1126/science.2432664
Yadav L, Puri N, Rastogi V et al (2015) Tumour angiogenesis and angiogenic inhibitors: a review. J Clin Diagn Res 9(6):XE01
pubmed: 26266204
pmcid: 4525594
Costache M, Ioana M, Iordache S et al (2015) VEGF expression in pancreatic cancer and other malignancies: a review of the literature. Rom J Intern Med 53(3):199–208
pubmed: 26710495
Ferrara N, Hillan KJ, Novotny W (2005) Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 333(2):328–335
doi: 10.1016/j.bbrc.2005.05.132
Lauro S, Onesti CE, Righini R et al (2014) The use of bevacizumab in non-small cell lung cancer: an update. Anticancer Res 34(4):1537–1545
pubmed: 24692680
Metzcar J, Wang Y, Heiland R et al (2019) A review of cell-based computational modeling in cancer biology. JCO Clin Cancer Inform 2:1–13
doi: 10.1200/CCI.18.00069
Vilanova G, Colominas I, Gomez H (2017) Computational modeling of tumor-induced angiogenesis. Arch Comput Methods Eng 24(4):1071–1102
doi: 10.1007/s11831-016-9199-7
Jones PF, Sleeman BD (2006) Angiogenesis—understanding the mathematical challenge. Angiogenesis 9(3):127–138
doi: 10.1007/s10456-006-9039-8
Milde F, Bergdorf M, Koumoutsakos P (2008) A hybrid model for three-dimensional simulations of sprouting angiogenesis. Biophys J 95(7):3146–3160
doi: 10.1529/biophysj.107.124511
Perfahl H, Hughes BD, Alarcón T et al (2017) 3D hybrid modelling of vascular network formation. J Theor Biol 414:254–268
Travasso RD, Corvera Poiré E, Castro M et al (2011) Tumor angiogenesis and vascular patterning: a mathematical model. PLoS One 6(5):e19989
doi: 10.1371/journal.pone.0019989
Zhao G, Yan W, Chen E et al (2013) Numerical simulation of the inhibitory effect of angiostatin on metastatic tumor angiogenesis and microenvironment. Bull Math Biol 75(2):274–287
doi: 10.1007/s11538-012-9805-2
Anderson AR, Weaver AM, Cummings PT et al (2006) Tumor morphology and phenotypic evolution driven by selective pressure from the microenvironment. Cell 127(5):905–915
doi: 10.1016/j.cell.2006.09.042
Jiang Y, Pjesivac-Grbovic J, Cantrell C et al (2005) A multiscale model for avascular tumor growth. Biophys J 89(6):3884–3894
doi: 10.1529/biophysj.105.060640
Peng L, Trucu D, Lin P et al (2017) A multiscale mathematical model of tumour invasive growth. Bull Math Biol 79(3):389–429
doi: 10.1007/s11538-016-0237-2
Shirinifard A, Gens JS, Zaitlen BL et al (2009) 3D multi-cell simulation of tumor growth and angiogenesis. PLoS One 4(10):e7190
doi: 10.1371/journal.pone.0007190
Lyu J, Cao J, Zhang P et al (2016) Coupled hybrid continuum-discrete model of tumor angiogenesis and growth. PLoS One 11(10):e0163173
doi: 10.1371/journal.pone.0163173
Mahlbacher G, Curtis LT, Lowengrub J et al (2018) Mathematical modeling of tumor-associated macrophage interactions with the cancer microenvironment. J Immunother Cancer 6(1):1–17
doi: 10.1186/s40425-017-0313-7
Salavati H, Soltani M, Amanpour S (2018) The pivotal role of angiogenesis in a multi-scale modeling of tumor growth exhibiting the avascular and vascular phases. Microvasc Res 119:105–116
doi: 10.1016/j.mvr.2018.05.001
Stéphanou A, Lesart A-C, Deverchère J et al (2017) How tumour-induced vascular changes alter angiogenesis: insights from a computational model. J Theor Biol 419:211–226
doi: 10.1016/j.jtbi.2017.02.018
Xu J, Vilanova G, Gomez H (2016) A mathematical model coupling tumor growth and angiogenesis. PLoS One 11(2):e0149422
doi: 10.1371/journal.pone.0149422
Yonucu S, Yιlmaz D, Phipps C et al (2017) Quantifying the effects of antiangiogenic and chemotherapy drug combinations on drug delivery and treatment efficacy. PLoS Comput Biol 13(9):e1005724
doi: 10.1371/journal.pcbi.1005724
Liang W, Zheng Y, Zhang J et al (2019) Multiscale modeling reveals angiogenesis-induced drug resistance in brain tumors and predicts a synergistic drug combination targeting EGFR and VEGFR pathways. BMC Bioinformatics 20(7):59–71
Wijeratne PA, Vavourakis V (2019) A quantitative in silico platform for simulating cytotoxic and nanoparticle drug delivery to solid tumours. Interface Focus 9(3):20180063
doi: 10.1098/rsfs.2018.0063
Xu J, Vilanova G, Gomez H (2017) Full-scale, three-dimensional simulation of early-stage tumor growth: the onset of malignancy. Comput Methods Appl Mech Eng 314:126–146
doi: 10.1016/j.cma.2016.07.010
Tang L, Van De Ven AL, Guo D et al (2014) Computational modeling of 3D tumor growth and angiogenesis for chemotherapy evaluation. PLoS One 9(1):e83962
doi: 10.1371/journal.pone.0083962
Maisonpierre PC, Suri C, Jones PF et al (1997) Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277(5322):55–60
doi: 10.1126/science.277.5322.55
Fagiani E, Christofori G (2013) Angiopoietins in angiogenesis. Cancer Lett 328(1):18–26
doi: 10.1016/j.canlet.2012.08.018
Yanagisawa H, Sugimoto M, Miyashita T (2021) Mathematical simulation of tumour angiogenesis: angiopoietin balance is a key factor in vessel growth and regression. Sci Rep 11(1):1–13
doi: 10.1038/s41598-020-79824-8
Holash J, Maisonpierre P, Compton D et al (1999) Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284(5422):1994–1998
doi: 10.1126/science.284.5422.1994